Navigation Links
Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
Date:11/1/2010

rrhosis, liver cancer, and liver transplantation worldwide" said Dr Michael W. Fried M.D., lead clinical investigator and Professor of Medicine, Director of Hepatology, University of North Carolina at Chapel Hill. "We are extremely encouraged by these data for TMC435."

The goal of HCV treatment is to achieve SVR24, which means the virus remains undetectable in patients' blood six months after they have finished treatment. Patients who achieve SVR are considered cured. The current standard of care for HCV, pegylated interferon combined with ribavirin, may cause debilitating side effects[i] and cures only about half of patients starting therapy for the first time.[1]

The most common adverse events were headache and fatigue, 46 percent and 42 percent in the TMC435 groups and 51 percent and 47 percent in the placebo group respectively. There were no clinically significant differences in frequency of rash, anemia or gastrointestinal events between the TMC435 groups and placebo. Most AEs were mild to moderate in severity. AEs leading to treatment discontinuation were reported in 7.1 percent of patients in TMC435 arms and 7.8 percent in placebo arm.

In laboratory parameters, significant decreases in transaminases (ALT and AST) were observed in all treatment groups. Small and transient bilirubin elevations (direct and indirect) were seen in the TMC435 150mg dose groups.

"With a strong heritage in virology, Tibotec is committed to improving the lives of those impacted by HCV through the development of innovative new treatment regimens," said Greg Fanning PhD, head of hepatitis C research and development at Tibotec. "TMC435 is an important component of our growing HCV pipeline and we are encouraged by the results of the interim analysis presented at the AASLD meeting."

TMC435 is also being studied in HCV genotype-1 treatment-experienced patients who have failed treatment with peg-interferon and ribavirin. The ASPIRE study (Antiviral STA
'/>"/>

SOURCE Medivir
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Medivir Interim Report, 1 January - 30 September 2010
2. Ethicon Endo-Surgery Studies Presented at DDW Demonstrate Potential of Pure NOTES Surgery With Companys Toolbox
3. First Patient of NOTES Investigational Device Exemption (IDE) Study Successfully Treated With Ethicon Endo-Surgery Devices
4. Cord Blood America Continues to Reduce Debt; Three Notes Retired
5. Par Pharmaceutical Announces Modified Dutch Auction Tender Offer to Purchase up to $65,000,000 Aggregate Principal Amount of its Currently Outstanding 2.875% Senior Subordinated Convertible Notes due 2010
6. Roper Industries Announces Senior Subordinated Convertible Notes Due 2034 to Accrue Contingent Cash Interest
7. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
8. Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes
9. Stryker Corporation Announces Pricing of Senior Notes
10. Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes
11. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... in two healthcare conferences during the third quarter, the ... Stanley Global Healthcare 2014 Conference.  Alexza,s corporate presentation will ... details on each event are below: , ... 2014 in Boston , MA.  The ...
(Date:7/29/2014)... -- Edwards Lifesciences Corporation (NYSE: EW ), the ... monitoring, today reported net income for the quarter ended June ... and non-GAAP net income of $94.0 million, or $0.88 per ... earlier was $93.3 million, or $0.81 per diluted share, and ... share.  Net sales for the quarter ended ...
(Date:7/29/2014)... -- New high priced hepatitis C drugs will increase ... $2.9 to $5.8 billion next year, according to a ... by the Pharmaceutical Care Management Association (PCMA). Milliman projects ... much as 8.6 percent in 2015 as a result ... The study finds that the majority of ...
Breaking Medicine Technology:Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
(Date:7/30/2014)... Bridgeport, Connecticut (PRWEB) July 30, 2014 ... released a new magnetic sports bracelet for pain relief ... 100 times strength carbonized titanium embedded in a silicone ... titanium. It also has Germanium and is embedded with ... magnetic balance bracelet. , “Pain Free Living has 12 ...
(Date:7/29/2014)... 30, 2014 VisitandCare.com today ... been added to the company’s exclusive network to help ... of joint efforts — as top fertility clinics in ... offer affordable, state-of-the-art, and successful IVF treatments. , The ... a comprehensive study by professionals at VisitandCare.com. The goal ...
(Date:7/29/2014)... MO (PRWEB) July 30, 2014 ... have recently been awarded the Patient-Centered Medical Home ... the National Committee for Quality Assurance. Only one ... NCQA Level I, Level 2, or Level 3 ... participate in Patient-Centered Medical Home report faster access ...
(Date:7/29/2014)... Dignity Sciences Limited, a privately held biopharmaceutical ... I trial with DS107G, an oral formulation of Dihomo ... randomized, placebo-controlled, double-blind, single-ascending and multiple dose Phase I ... of food on DS107G in healthy subjects. , ... following both single and multiple oral doses over 28 ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip indicates ... as all other disturbing symptoms that hemorrhoids commonly causes. ... researcher and natural medicine expert. , The author ... to the elimination of symptoms such as itching, burning, ... Learn more about the H Miracle by visiting the ...
Breaking Medicine News(10 mins):Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2
... for growth hormone therapy’s anti-aging powers – says a team ... papers based on growth hormone.// ,'There is certainly ... to an otherwise healthy person will make him or her ... potential for adverse side effects.' - says Dr. Hau Liu, ...
... a member of a large family may not be best ... greatly influenced the development of stomach cancer linked to the ... to be especially vulnerable to the most common type of ... the records of more than 7,000 Japanese-American men who were ...
... have reported an interesting find: statins, or drugs used ... actually have an added benefit; //reduce the chance of ... Australians use pop statins, which are lipid-modifying drugs that ... drug for reducing cholesterol levels. , The drug ...
... ideal world, the answer is no, as breast milk ... ,However, in the same developing countries where the ... is often considered the only safe and nutritious food ... research is needed. ,A new study conducted ...
... true; for fat people and inventors. ,Scientists have always ... Britain are no exception. //Currently, two thirds of the population can ... to put a morbidly obese figure of 2.2 million pounds ... London. ,Bloom’s quest is to create a chewing gum or ...
... chicken eggs that can be used to produce drugs like those ... at Edinburgh, Scotland have claimed to create a flock ... to create life saving drugs. ,These drugs could ... National Health Service incurs, according to them. , For ...
Cached Medicine News:Health News:Is Growth Hormone – a Key to Longevity 2Health News:Link Between Family Size and Stomach Cancer Found 2Health News:Link Between Family Size and Stomach Cancer Found 3Health News:Chew That Fat Away 2Health News:No Pills Just Omelets 2
... The Vasotrax is an ... pressure and heart rate non-invasively, ... fact, significantly more accurate than ... On a full battery charge, ...
... Inhibins are heterodimeric proteins that suppress the ... the pituitary. Inhibin consists of two distinct ... together. Inhibin A consists of the alpha-subunit ... alpha-subunit and betaB-subunit. Only the dimeric forms ...
... II (IGF-II) is a 7.5 kDa peptide which ... postulated to have mitogenic and metabolic actions involved ... mediated by binding to target cell receptors. IGF-II ... IGF receptor, a monomeric protein which also serves ...
... A (PAPP-A) is a large placenta-derived ... high concentrations by placental trophoblast cells, ... circulation in increasing concentrations throughout gestation ... specific to pregnancy since measurable levels ...
Medicine Products: